Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia.

about

Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia.

Item

http://www.wikidata.org/entity/Q43097246

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia.

@en

Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia.

@nl

type

Item

label

Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia.

@en

Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia.

@nl

prefLabel

Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia.

@en

Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia.

@nl

P1476

Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia.

@en

P2093

E S Costa

http://www.w3.org/2001/XMLSchema#string

F F Dutra

http://www.w3.org/2001/XMLSchema#string

G A P Oliveira

http://www.w3.org/2001/XMLSchema#string

I B Otazu

http://www.w3.org/2001/XMLSchema#string

M C Guerra

http://www.w3.org/2001/XMLSchema#string

M D Tabernero

http://www.w3.org/2001/XMLSchema#string

M S Freitas

http://www.w3.org/2001/XMLSchema#string

S F Maia

http://www.w3.org/2001/XMLSchema#string

P2860

Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene

Treatment of CML in pediatric patients: should imatinib mesylate (STI-571, Gleevec) or allogeneic hematopoietic cell transplant be front-line therapy?

Response to alpha-interferon in children with Philadelphia chromosome-positive chronic myelocytic leukemia.

Alpha-interferon in combination with cytarabine in children with Philadelphia chromosome-positive chronic myeloid leukemia.

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.

Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.

Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study.

Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation.

The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib.

P304

580-584

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1590/S0100-879X2010007500026

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jerson L Silva

Radovan Borojevic

P577

2010-04-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43161350

http://www.w3.org/2001/XMLSchema#string

P698

20396859

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia